BAKER BROS. ADVISORS LP Q1 2017 Filing

Filed May 15, 2017

Portfolio Value

$12.2T

Holdings

119

Report Date

Q1 2017

Filing Type

13F-HR

All Holdings (119 positions)

#StockSharesValue% PortfolioType
101
Immune Design Corp.
148,937$1.0B0.01%
102
Affimed N.V.
400,000$920.0M0.01%
103
MDGLMadrigal Pharmaceuticals, Inc.
57,762$890.0M0.01%
104
XLRNAcceleron Pharma Inc.
28,765$761.0M0.01%
105
CMRXEURChimerix, Inc.
115,216$735.0M0.01%
106
Five Prime Therapeutics, Inc.
19,247$696.0M0.01%
107
Palatin Technologies, Inc.
2,050,000$671.0M0.01%
108
I9DNArbutus Biopharma Corporation
180,582$587.0M0.00%
109
Ritter Pharmaceuticals, Inc.
400,000$568.0M0.00%
110
ADAPYAdaptimmune Therapeutics plc
100,000$551.0M0.00%
111
Proteon Therapeutics, Inc.
298,591$523.0M0.00%
112
Bioverativ Inc.
8,249$449.0M0.00%
113
DVAXDynavax Technologies Corporation
75,000$446.0M0.00%
114
BioDelivery Sciences International, Inc.
210,021$399.0M0.00%
115
CCXIEURChemoCentryx, Inc.
49,064$357.0M0.00%
116
Windtree Therapeutics, Inc.
254,973$291.0M0.00%
117
BioPharmX Corporation
377,295$191.0M0.00%
118
BGMS 6 PERPCyclacel Pharmaceuticals, Inc.
13,253$83.0M0.00%
119
BioTime, Inc.
20,084$12.0M0.00%
PreviousPage 2 of 2